← Back to Search

Checkpoint Inhibitor

Vibostolimab + Pembrolizumab for Advanced Cancer

Phase 1
Waitlist Available
Research Sponsored by Merck Sharp & Dohme Corp.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Has an Eastern Cooperative Oncology Group performance status of 0 to 1
Females must not be pregnant
Must not have
Has received previous treatment with an immunomodulatory agent (e.g., anti-programmed cell death 1, anti-programmed cell death ligand 1 or cytotoxic T-lymphocyte-associated protein 4) and was discontinued from that treatment due to a Grade 3 or higher immune-related adverse event
Is on chronic systemic steroid therapy in excess of replacement doses or on any other form of immunosuppressive medication
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new drug called vibostolimab, alone or with another drug called pembrolizumab, in adults with advanced cancers who have no other treatment options. The goal is to see if these drugs are safe and effective in helping the immune system fight cancer.

Who is the study for?
This trial is for adults with advanced solid tumors and no remaining treatment options expected to help. Participants must have measurable disease, be in good physical condition, not pregnant, agree to use contraception, and provide a tumor sample. Specific groups include Chinese from mainland China or Japanese descent with certain cancers who haven't had anti-PD-1/PD-L1 therapy.
What is being tested?
The study tests vibostolimab alone and combined with pembrolizumab (with or without chemotherapy) in metastatic solid tumors. It aims to find the safest dose that can be given (RPTD), assess how the body processes these drugs, and evaluate their effectiveness against cancer.
What are the potential side effects?
Potential side effects may include immune-related reactions due to immunotherapy agents like pembrolizumab/vibostolimab which could affect organs; infusion reactions; fatigue; digestive issues; blood disorders; increased risk of infections.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can carry out all my usual activities without help.
Select...
I am not pregnant.
Select...
I have a metastatic solid tumor with no beneficial treatment options available.
Select...
My cancer has spread and this was confirmed by a lab test.
Select...
I have stage IV non-squamous NSCLC confirmed by tests.
Select...
I have provided a sample of my tumor for testing.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I stopped an immune therapy due to a severe side effect.
Select...
I am taking high doses of steroids or other drugs that weaken my immune system.
Select...
I cannot or will not take folic acid or Vitamin B12 supplements.
Select...
I have cancer that has spread to my brain or spinal cord.
Select...
I am currently being treated for an infection.
Select...
I have had pneumonitis treated with steroids.
Select...
I have had a bone marrow or organ transplant.
Select...
I am HIV positive or have active Hepatitis B or C.
Select...
I have been treated with a drug targeting the TIGIT receptor before.
Select...
I have interstitial lung disease.
Select...
I have fluid buildup in my abdomen or around my lungs.
Select...
I still experience side effects from cancer treatment received over 4 weeks ago.
Select...
I haven't had cancer treatment or major surgery in the last 4 weeks.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

11Treatment groups
Experimental Treatment
Group I: vibostolimab+pembrolizumab+carboplatin OR cisplatin+etoposideExperimental Treatment5 Interventions
Participants will receive 200 mg vibostolimab in combination with 200 mg pembrolizumab, plus the investigator's choice of Area Under Curve (AUC) 5 mg/mL/min carboplatin OR 75 mg/m\^2 cisplatin on Day 1 of each 21-day cycle plus 100 mg/m\^2/day etoposide on Days 1-3 of each 21-day cycle for up to 4 cycles. Maintenance therapy with 200 mg vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day cycle will continue for up to an additional 31 cycles. A participant will be allowed to switch from cisplatin to carboplatin in the event of an adverse event (AE), ineligibility for further cisplatin therapy, and/or the investigator considers switching to carboplatin to be in the best interest of the participant.
Group II: vibostolimab Dose 2 Japanese cohortExperimental Treatment2 Interventions
Japanese participants will be randomized to receive a fixed dose (Dose 2) of vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
Group III: vibostolimab Dose 1 Japanese cohortExperimental Treatment2 Interventions
Japanese participants will be randomized to receive a fixed dose (Dose 1) of vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
Group IV: vibostolimab +pembrolizumab+pemetrexed+carboplatinExperimental Treatment4 Interventions
Participants will receive a fixed dose of vibostolimab in combination with 200 mg pembrolizumab, 500 mg/m\^2 pemetrexed, and Area Under Curve (AUC) 5 mg/mL/min carboplatin on Day 1 of each 21-day infusion cycle for up to 4 cycles followed by maintenance therapy with a fixed dose of vibostolimab in combination with 200 mg pembrolizumab and 500 mg/m\^2 pemetrexed on Day 1 of each 21-day infusion cycle for up to an additional 31 cycles.
Group V: vibostolimab + pembrolizumabExperimental Treatment2 Interventions
During an initial dose evaluation phase, participants will receive Dose A, B, C, D, E, or F of vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle (for a maximum of 35 cycles) until the RPTD of vibostolimab has been established. The RPTD will be established based on the number of DLTs at each dose level. Once the RPTD of vibostolimab is established, participants will continue receiving the RPTD of vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
Group VI: vibostolimabExperimental Treatment1 Intervention
During an initial dose evaluation phase, participants will receive Dose A, B, C, D, E, or F of vibostolimab on Day 1 of each 21-day infusion cycle (for a maximum of 35 cycles) until the RPTD has been established. The RPTD will be established based on the number of dose limiting toxicities (DLTs) at each dose level. Once the RPTD is established, participants will continue receiving the RPTD of vibostolimab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
Group VII: pembrolizumab/vibostolimab coformulation China cohortExperimental Treatment1 Intervention
Participants from mainland China will receive a fixed dose of pembrolizumab/vibostolimab coformulation, consisting of 200 mg of pembrolizumab + 200 mg vibostolimab, on Day 1 of each 21-day infusion cycle for up to 35 cycles.
Group VIII: pembrolizumab/vibostolimab coformulationExperimental Treatment1 Intervention
Participants will receive a fixed dose of pembrolizumab/vibostolimab coformulation, consisting of 200 mg of pembrolizumab + 200 mg vibostolimab, on Day 1 of each 21-day infusion cycle for up to 35 cycles.
Group IX: Randomized dose 2 comparison cohortExperimental Treatment2 Interventions
Participants will be randomized to receive a fixed dose (Dose 2) of vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
Group X: Randomized dose 1 comparison cohortExperimental Treatment2 Interventions
Participants will be randomized to receive a fixed dose (Dose 1) of vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
Group XI: Advanced solid tumor cohortExperimental Treatment2 Interventions
Participants will receive the RPTD of vibostolimab monotherapy or the RPTD of vibostolimab in combination with 200 mg pembrolizumab on Day 1 of each 21-day infusion cycle until the 35-cycle limit is reached.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
vibostolimab
2016
Completed Phase 1
~470
pembrolizumab
2017
Completed Phase 3
~5890
pemetrexed
2005
Completed Phase 3
~5000
carboplatin
2010
Completed Phase 3
~4790
pembrolizumab/vibostolimab coformulation
2016
Completed Phase 1
~470
cisplatin
1997
Completed Phase 3
~3290
etoposide
1994
Completed Phase 3
~9300

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for tumors, particularly immunotherapies like Vibostolimab (an anti-TIGIT monoclonal antibody), work by enhancing the body's immune response against cancer cells. Vibostolimab blocks the TIGIT pathway, which tumors use to evade immune detection. By inhibiting this pathway, it reactivates T-cells to recognize and destroy cancer cells. This targeted approach is significant for tumor patients as it boosts the immune system's ability to fight cancer, potentially improving outcomes and reducing side effects compared to traditional therapies.
Inclusion body myositis: update.

Find a Location

Who is running the clinical trial?

Merck Sharp & Dohme Corp.Lead Sponsor
2,286 Previous Clinical Trials
4,581,739 Total Patients Enrolled
5 Trials studying Tumors
149 Patients Enrolled for Tumors
Merck Sharp & Dohme LLCLead Sponsor
4,007 Previous Clinical Trials
5,184,630 Total Patients Enrolled
11 Trials studying Tumors
2,324 Patients Enrolled for Tumors
Medical DirectorStudy DirectorMerck Sharp & Dohme LLC
2,883 Previous Clinical Trials
8,088,215 Total Patients Enrolled
2 Trials studying Tumors
34 Patients Enrolled for Tumors

Media Library

Pembrolizumab (Checkpoint Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT02964013 — Phase 1
Tumors Research Study Groups: pembrolizumab/vibostolimab coformulation, vibostolimab Dose 2 Japanese cohort, Advanced solid tumor cohort, vibostolimab Dose 1 Japanese cohort, vibostolimab + pembrolizumab, vibostolimab +pembrolizumab+pemetrexed+carboplatin, Randomized dose 1 comparison cohort, Randomized dose 2 comparison cohort, vibostolimab, vibostolimab+pembrolizumab+carboplatin OR cisplatin+etoposide, pembrolizumab/vibostolimab coformulation China cohort
Tumors Clinical Trial 2023: Pembrolizumab Highlights & Side Effects. Trial Name: NCT02964013 — Phase 1
Pembrolizumab (Checkpoint Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02964013 — Phase 1
~53 spots leftby Nov 2025